Penn Pharma and Xcelience, LLC today announced that the two companies have entered into a joint venture agreement to provide Capsugel’s Xcelodose® precision powder micro-dosing system technology on a global basis.
The joint venture provides pharmaceutical and biotechnology companies the opportunity to manufacture first in human batches faster and closer to the clinical sites. The companies will operate the largest network of Xcelodose® systems worldwide guaranteeing immediate manufacturing capacity.
“This joint venture will create a powerful partnership between two leading providers who share a common commitment to quality, innovation, and building client relationships based on trust and performance,” said Derek Hennecke, CEO & President of Xcelience. “Xcelience has more than six years experience in powder in capsule technology and has processed more than 100 clinical supply batches using the Xcelodose technology,” notes Paul Wituschek, Global Sales & Marketing Director of Penn. “Penn will be able to immediately leverage this expertise to provide this important accelerated development option to our clients.”
Xcelodose is a registered trademark of Capsugel, a division of Pfizer.
Penn Pharma is a leading provider of fully integrated and cost effective pharmaceutical development and custom manufacturing services to the international healthcare industry, whose services support a fast and effective route from clinic to market. Penn provides unparalleled service offerings developed over its 30 year trading history. Penn’s core services include formulation development, analytical development & stability studies, clinical trial supply – packing and labeling, storage and distribution, clinical and commercial manufacturing, Qualified Person (QP) Release services and commercial product sourcing for clinical trials. For more detailed information about Penn, visit www.pennpharm.com.
Xcelience LLC, is a contract research organization which has been providing formulation development, preformulation, analytical, and clinical trial manufacturing since 1997. The company has a solid reputation for accelerating early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience’s unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab.
